TapewireFind a company

person · Reporting owner

Balthaser Kevin

Disclosed activity across 1 company

Tapewire entity
63153
SEC CIK
0001957554

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Aclaris Therapeutics, Inc.ACRS · Entity 5041Chief Financial OfficerMarch 01, 2026March 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aclaris Therapeutics, Inc.

Report date March 01, 2026 · Filed March 03, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect187,453 Ending reported balance After 2026-03-01 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-03-01 · Exercise / conversion · Acquired 2,375 · Balance 188,130

F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Row 2 · 2026-03-01 · Tax withholding · Disposed 677 · Balance 187,453

F2: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2026-03-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-03-01 · Exercise / conversion · Disposed 2,375 · Balance 0

F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F3: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F2: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.

F3: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of the applicable vesting date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 01, 2024 Filed Mar 5, 2024 22:02 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Tax withholdingCommon Stock 313 $1.24 $388.12
Disclosure

SEC source: 0001209191-24-004397 · doc4.xml · nonDerivative · entry 2

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,212

F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.

Read SEC document
March 01, 2024 Filed Mar 5, 2024 22:02 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionCommon Stock 1,100 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-24-004397 · doc4.xml · nonDerivative · entry 1

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,525

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Read SEC document
February 01, 2024 Filed Feb 6, 2024 00:27 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 GrantRestricted Stock Units · Derivative 147,500 $0.00 $0.00
Disclosure

SEC source: 0001209191-24-002836 · doc4.xml · derivative · entry 3

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 147,500

Underlying: Common Stock · 147,500 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F4 · derivative.exercise_date: 50% of the shares underlying these restricted stock units vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

F4 · derivative.expiration_date: 50% of the shares underlying these restricted stock units vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

Read SEC document
February 01, 2024 Filed Feb 6, 2024 00:27 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 GrantRestricted Stock Units · Derivative 59,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-24-002836 · doc4.xml · derivative · entry 2

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,000

Underlying: Common Stock · 59,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

Read SEC document
February 01, 2024 Filed Feb 6, 2024 00:27 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 GrantEmployee Stock Option (Right to Buy) · Derivative 206,500 $0.00 Strike: $1.20 $0.00
Disclosure

SEC source: 0001209191-24-002836 · doc4.xml · derivative · entry 1

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 206,500

Underlying: Common Stock · 206,500 shares

Expires 2034-01-31

F1 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

Read SEC document
January 01, 2024 Filed Jan 3, 2024 21:47 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionRestricted Stock Units · Derivative 7,500 $0.00 $0.00
Disclosure

SEC source: 0001209191-24-000425 · doc4.xml · derivative · entry 3

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 7,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F3 · derivative.exercise_date: On February 1, 2023, the Reporting Person was granted 30,000 restricted stock units. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

F3 · derivative.expiration_date: On February 1, 2023, the Reporting Person was granted 30,000 restricted stock units. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

Read SEC document
January 01, 2024 Filed Jan 3, 2024 21:47 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Tax withholdingCommon Stock 2,536 $1.05 $2,662.80
Disclosure

SEC source: 0001209191-24-000425 · doc4.xml · nonDerivative · entry 2

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,425

F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.

Read SEC document
January 01, 2024 Filed Jan 3, 2024 21:47 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionCommon Stock 7,500 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-24-000425 · doc4.xml · nonDerivative · entry 1

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,961

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Read SEC document
September 06, 2023 Filed Sep 7, 2023 20:16 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 PurchaseCommon Stock 9,490 $7.90 $74,971.00
Disclosure

SEC source: 0001209191-23-048612 · doc4.xml · nonDerivative · entry 1

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,461

Read SEC document
September 01, 2023 Filed Sep 5, 2023 21:08 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionRestricted Stock Units · Derivative 1,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-048199 · doc4.xml · derivative · entry 3

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000

Underlying: Common Stock · 1,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F3 · derivative.exercise_date: The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of September 1, 2023 and September 1, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

F3 · derivative.expiration_date: The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of September 1, 2023 and September 1, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

Read SEC document
September 01, 2023 Filed Sep 5, 2023 21:08 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Tax withholdingCommon Stock 285 $7.90 $2,251.50
Disclosure

SEC source: 0001209191-23-048199 · doc4.xml · nonDerivative · entry 2

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,971

F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.

Read SEC document
September 01, 2023 Filed Sep 5, 2023 21:08 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionCommon Stock 1,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-048199 · doc4.xml · nonDerivative · entry 1

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,256

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Read SEC document
March 03, 2023 Filed Mar 4, 2023 01:09 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 SaleCommon Stock 894 $12.63 $11,289.52
Disclosure

SEC source: 0001209191-23-016063 · doc4.xml · nonDerivative · entry 6

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,256

F4 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 and March 2, 2023 pursuant to preexisting sell-to-cover elections.

F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.47 to $12.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
March 02, 2023 Filed Mar 4, 2023 01:09 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionRestricted Stock Units · Derivative 1,500 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016063 · doc4.xml · derivative · entry 10

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500

Underlying: Common Stock · 1,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F9 · derivative.exercise_date: The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of March 2, 2023 and March 2, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

F9 · derivative.expiration_date: The shares underlying these restricted stock units vest over a period of two years, with one-half of the shares vesting on each of March 2, 2023 and March 2, 2024, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

Read SEC document
March 02, 2023 Filed Mar 4, 2023 01:09 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionCommon Stock 1,500 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016063 · doc4.xml · nonDerivative · entry 5

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,150

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Read SEC document
March 02, 2023 Filed Mar 4, 2023 01:09 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 SaleCommon Stock 1,000 $12.29 $12,289.00
Disclosure

SEC source: 0001209191-23-016063 · doc4.xml · nonDerivative · entry 4

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,650

F2 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 pursuant to preexisting sell-to-cover elections.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.96 to $12.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
March 01, 2023 Filed Mar 4, 2023 01:09 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionRestricted Stock Units · Derivative 2,375 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016063 · doc4.xml · derivative · entry 9

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,125

Underlying: Common Stock · 2,375 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F8 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

F8 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date.

Read SEC document
March 01, 2023 Filed Mar 4, 2023 01:09 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionRestricted Stock Units · Derivative 1,100 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016063 · doc4.xml · derivative · entry 8

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,200

Underlying: Common Stock · 1,100 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F7 · derivative.exercise_date: The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

F7 · derivative.expiration_date: The shares underlying these restricted stock units vest over a period of three years, with one-third of the shares vesting on each of March 1, 2023, March 1, 2024 and March 1, 2025, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

Read SEC document
March 01, 2023 Filed Mar 4, 2023 01:09 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionRestricted Stock Units · Derivative 1,475 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-016063 · doc4.xml · derivative · entry 7

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,475 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F6 · derivative.exercise_date: The shares underlying these restricted stock units vest on March 1, 2023, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

F6 · derivative.expiration_date: The shares underlying these restricted stock units vest on March 1, 2023, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

Read SEC document
March 01, 2023 Filed Mar 4, 2023 01:09 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionCommon Stock 2,375 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016063 · doc4.xml · nonDerivative · entry 3

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,650

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Read SEC document
March 01, 2023 Filed Mar 4, 2023 01:09 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionCommon Stock 1,100 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016063 · doc4.xml · nonDerivative · entry 2

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,275

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Read SEC document
March 01, 2023 Filed Mar 4, 2023 01:09 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 Exercise / conversionCommon Stock 1,475 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-016063 · doc4.xml · nonDerivative · entry 1

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,175

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

Read SEC document
February 01, 2023 Filed Feb 3, 2023 21:55 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 GrantRestricted Stock Units · Derivative 30,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-006969 · doc4.xml · derivative · entry 2

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

Read SEC document
February 01, 2023 Filed Feb 3, 2023 21:55 UTC Aclaris Therapeutics, Inc. ACRS · Entity 5041 GrantEmployee Stock Option (Right to Buy) · Derivative 105,000 $0.00 Strike: $16.97 $0.00
Disclosure

SEC source: 0001209191-23-006969 · doc4.xml · derivative · entry 1

Balthaser Kevin · CIK 0001957554 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 105,000 shares

Expires 2033-01-31

F1 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.